Aranda Pharma Ltd

Finland

Back to Profile

1-5 of 5 for Aranda Pharma Ltd Sort by
Query
Patent
Aggregations Reset Report
Jurisdiction
        United States 3
        Canada 1
        World 1
IPC Class
A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof 2
A61K 31/542 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems 2
C07D 213/30 - Oxygen atoms 2
C07D 213/57 - Nitriles 2
C07D 213/61 - Halogen atoms or nitro radicals 2
See more
Found results for  patents

1.

Use of condensed benzo[B]thiazine derivatives as cytoprotectants

      
Application Number 14894683
Grant Number 09827249
Status In Force
Filing Date 2014-05-30
First Publication Date 2016-04-21
Grant Date 2017-11-28
Owner ARANDA PHARMA LTD (Finland)
Inventor
  • Ratilainen, Jari
  • Goldsteins, Gundars

Abstract

The present invention relates to arylthiazine compounds, metabolites, N-oxides, amides, esters, pharmaceutically acceptable salts, hydrates and solvates thereof and their use as cytoprotectants in the treatment or prophylaxis of diseases or states, either acute or chronic, involving aberrant cellular lipid peroxidation in the central nervous system or in the periphery of the body. The present invention also relates to a method for their preparation and to pharmaceutical composition comprising as an active ingredient one or more of the aforementioned compounds.

IPC Classes  ?

  • A61K 31/542 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
  • C07D 513/04 - Ortho-condensed systems
  • C07D 513/20 - Spiro-condensed systems
  • A61K 31/547 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems
  • C07D 513/10 - Spiro-condensed systems

2.

Heteroarylamide derivatives having antiandrogenic properties

      
Application Number 14371927
Grant Number 09650382
Status In Force
Filing Date 2013-01-11
First Publication Date 2015-01-01
Grant Date 2017-05-16
Owner ARANDA PHARMA LTD (Finland)
Inventor
  • Ratilainen, Jari
  • Koistinaho, Milla
  • Muona, Anu

Abstract

B, R1 1, R′, R″, z and X are as defined in the claims. The arylamide derivatives of formula (I) have antiandrogenic properties. The invention also relates to compounds of formula (I) for use as a medicament and to pharmaceutical compositions comprising them and to their preparation.

IPC Classes  ?

  • A01N 43/58 - 1,2-DiazinesHydrogenated 1,2-diazines
  • A61K 31/60 - Salicylic acidDerivatives thereof
  • A61K 31/50 - PyridazinesHydrogenated pyridazines
  • A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
  • A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
  • A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
  • C07D 487/00 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups
  • C07D 213/00 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D 211/78 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
  • C07D 211/90 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
  • C07D 213/84 - Nitriles
  • C07D 487/04 - Ortho-condensed systems
  • C07D 213/30 - Oxygen atoms
  • C07D 213/57 - Nitriles
  • C07D 213/61 - Halogen atoms or nitro radicals
  • A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
  • A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
  • C07D 213/89 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
  • C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

3.

USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS

      
Application Number FI2014050432
Publication Number 2014/191632
Status In Force
Filing Date 2014-05-30
Publication Date 2014-12-04
Owner ARANDA PHARMA LTD (Finland)
Inventor
  • Ratilainen, Jari
  • Goldsteins, Gundars

Abstract

The present invention relates to arylthiazine compounds, metabolites, N-oxides, amides, esters,pharmaceutically acceptable salts, hydrates and solvates thereof and their use as cytoprotectants in the treatment or prophylaxis of diseases or states, either acute or chronic, involving aberrant cellular lipid peroxidation in the central nervous system or in the periphery of the body. The present invention also relates to a method for their preparation and to pharmaceutical composition comprising as an active ingredient one or more of the aforementioned compounds.

IPC Classes  ?

  • C07D 513/04 - Ortho-condensed systems
  • C07D 513/20 - Spiro-condensed systems
  • A61K 31/542 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

4.

HETEROARYLAMIDE DERIVATIVES HAVING ANTIANDROGENIC PROPERTIES

      
Document Number 02861713
Status In Force
Filing Date 2013-01-11
Open to Public Date 2013-07-18
Grant Date 2021-08-31
Owner ARANDA PHARMA LTD (Finland)
Inventor
  • Ratilainen, Jari
  • Koistinaho, Milla
  • Muona, Anu

Abstract

The invention relates to heteroarylamide derivatives having formula (I)(see formula I)and an N-oxide, a stereoisomer and a pharmaceutically acceptable salt thereof. The arylamide derivatives of formula (I) have antiandrogenic properties. The invention also relates to compounds of formula (I) for use as a medicament and to pharmaceutical compositions comprising them and to their preparation.

IPC Classes  ?

5.

Arylamide derivatives having antiandrogenic properties

      
Application Number 13809787
Grant Number 08816119
Status In Force
Filing Date 2011-07-14
First Publication Date 2013-05-02
Grant Date 2014-08-26
Owner ARANDA PHARMA LTD (Finland)
Inventor
  • Ratilainen, Jari
  • Koistinaho, Milla
  • Muona, Anu

Abstract

The invention relates to novel arylamide derivatives having formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, where R1-R11, R′, R″, z and X are as defined in the claims. The arylamide derivatives of formula (I) have antiandrogenic properties. The invention also relates to compounds of formula (I) for use as a medicament and to pharmaceutical compositions comprising them and to their preparation.

IPC Classes  ?

  • C07C 255/03 - Mononitriles
  • A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine